Navigation Links
Georgia Kids 'Kick Butts' on April 2
Date:3/27/2008

ey. A report about the poll findings and the impact of tobacco marketing on youth can be found at: http://www.tobaccofreekids.org/kbd2008poll

To protect kids from tobacco addiction and save lives, health advocates are urging Congress to pass pending legislation (S. 625/H.R. 1008) granting the FDA authority to regulate tobacco products. The House Energy and Commerce Committee is expected to vote on the legislation on Kick Butts Day (April 2). Representative John Barrow (D-GA) is a member of that committee and a cosponsor of the legislation.

Among other things, the legislation would grant the FDA authority to crack down on tobacco marketing and sales to kids; require that tobacco companies disclose the contents of their products and reduce or remove harmful ingredients; stop tobacco companies from misleading the public about the health risks of tobacco products; and require larger, more effective health warnings on tobacco products.

"It is unacceptable that tobacco products are the number one cause of preventable death in the United States, yet they are virtually unregulated to protect our kids and the nation's health," said William V. Corr, Executive Director of the Campaign for Tobacco-Free Kids. "By granting the FDA authority over tobacco products, Congress can stop the tobacco industry from targeting our children and misleading the public. We hope Kick Butts Day will inspire our nation's leaders to take effective action to protect children and save lives."

At the state level, health advocates are urging governors and legislators to adopt proven measures to reduce tobacco use and exposure to secondhand smoke, including higher tobacco taxes, smoke-free workplace laws, and well-funded programs to prevent kids from smoking and help smokers quit.

Since the 1998 tobacco settlement, tobacco companies have nearly doubled their annual marketing expenditures,
'/>"/>

SOURCE Campaign for Tobacco-Free Kids
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Wellness Initiative for 2008 Tour de Georgia Presented by AT&T Led by New Partnership With Blue Cross and Blue Shield of Georgia
2. Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon
3. Vendormate Again Selected as Top 40 Georgia Innovative Technology Company
4. Farm Bill Provision Will Disrupt Georgia Medicaid Program
5. 2008 Georgia Walk for Autism Supporters Gather in Atlanta for Kick-Off Dinner
6. CEO Addresses Georgia Business Leaders About Developing Pandemic and Business Continuity Plans
7. New Options for Medicare Beneficiaries in Georgia
8. Georgia Cancer Specialists to Sponsor Sixth Annual Totes 2 Tots Suitcase Drive for Foster Children
9. AMERIGROUP Community Care of Georgia Wins New Health Plan Accreditation from NCQA
10. BB&T Insurance Services to acquire Georgia agency
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...- The Providence Service,Corporation (Nasdaq: P...mpany,s,Chief Operating Officer, has been appoint...is, appointment fills the vacancy left by the Apri...rns the board to six members. Mr.,Norris will no.... Norris, age 41, has been with Providence since i...
(Date:11/21/2008)...ennox-Gastaut syndrome , , FRIDAY, Nov. ...ufinamide) has been approved as a supplementary tr...x-Gastaut syndrome, the U.S. Food and Drug Adminis...sed on results of a four-month clinical trial that...nts who took a placebo, those who took the drug ha...
(Date:11/21/2008)...re/ -- New research at West Virginia University ... product aimed at young adults is catching on. And...l Snus - touted as a socially acceptable way to sa...s of nicotine. , , "Camel Snus contains mor...ruce Adkins of the state Division of Tobacco Preve...
(Date:11/21/2008)... -- U.S. News & World Report and the National ...Choice(R) HealthPlan of South Carolina in the top ...d in U.S. News & World Report,s issue this wee...he nation,s best health plans based on clinical qu...scores. NCQA and U.S. News & World Report rank...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...u.s., mothers who breastfed their babies in public... act was made to prove that breastfeeding was an a...h mother and child. The U.S. Healthy People 2010 ...n of mothers who choose to breastfeed their babies...
... National Institutes of Health (NIH) and the Cente...oday that more than one-third of adults having dia...abetes in adults aged 20 and older has increased f...period between 1988 to 1994 and 1999 to 2002. How...
...ervations on one side and on the other side increa... does not suffer is the UPA Government’s please-a...eft supporters announced that 27 per cent of the s...ns would be available to Other Backward Classes (O...
...une diseases, named Juvenile rheumatoid arthritis ...which inversely affect health-related quality of l...gests patient prognosis in adults – study finds. B...d. Arthritis Care & Research journal published a...
Other Medicine News:Health News:Breastfeeding Mothers Arrested For Public Indecency 2Health News:Undetected Cases Of Diabetes Boom In The US 2Health News:Undetected Cases Of Diabetes Boom In The US 3Health News:Undetected Cases Of Diabetes Boom In The US 4Health News:The Government’s Balancing Act on Reservatio 2Health News:The Government’s Balancing Act on Reservatio 3Health News:Socioeconomic Status Plays A Role In Juvenile Rheumatoid Arthritis 2
(Date:11/20/2008)...wire/ -- Epeius Biotechnologies,announced today t... in,chemotherapy-resistant metastatic soft tissue...nt P. Chawla, principal investigator, at the CTOS ...r 13-15, 2008. Patients received,repeated infusio...nalysis of,safety and efficacy data showed no maj...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...linical data from a prospective,registry presente...ws DVT,treatment with the Trellis(R) Peripheral I... Clara, CA) successfully breaks up the blood clot ...is technique, called isolated pharmacomechanical t... safely than current catheter-directed thrombolysi...
(Date:11/19/2008)...tatistical significance , , ISELIN, N.J., N...ion (Nasdaq: PARS ) today announced results from...ulsion (NE) drug delivery technology formulated wi...lti-center, randomized, double-blinded, placebo-co...f the Company,s 3% Diclofenac Diethanolamine NanoE...
Breaking Medicine Technology:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Off Hours Heart Patients Less Likely to Get Angioplasty 17343 1Off Hours Heart Patients Less Likely to Get Angioplasty 17343 2Analysis of RNA role in spreading disease advances study of damaging plant infections 2981 1Analysis of RNA role in spreading disease advances study of damaging plant infections 2981 2Analysis of RNA role in spreading disease advances study of damaging plant infections 2981 3Analysis of RNA role in spreading disease advances study of damaging plant infections 2981 4Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results 4742 1Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results 4742 2Crop management strategies key to a healthy Gulf planet 2980 1Crop management strategies key to a healthy Gulf planet 2980 2Crop management strategies key to a healthy Gulf planet 2980 3
...ong ADHD Patients Nearly Triple That,of General Po..., INDIANAPOLIS, May 23, 2007 /PRNewswire-FirstCall...ttera(R) (atomoxetine HCl),improved symptoms of At...patients with comorbid alcohol abuse disorder, sug... with Strattera in,patients with both disorders. R...
...ty Demonstrated Among Patients with,Active Disease... --,ChemoCentryx, Inc., a clinical-stage biopharma...g and commercializing,orally-administered therapeu...ata today from the company,s Phase 2 clinical tria...-inflammatory agent,that targets the chemokine rec...
Other Medicine Technology:Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 2Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 3Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 4Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 5Study Suggests Strattera Improved ADHD Symptoms in Patients With,Comorbid Alcohol Abuse 6ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 2ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 4ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 5
Ideal for chest procedures.
Male Compression Vests
Female Compression VEST w/sleeves
Male Support Brief
Medicine Products: